Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 3
2008 3
2009 4
2010 5
2011 4
2012 3
2013 1
2015 3
2016 7
2017 9
2018 9
2019 8
2020 14
2021 6
2022 3
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Bortezomib in multiple myeloma.
Terpos E, Roussou M, Dimopoulos MA. Terpos E, et al. Among authors: roussou m. Expert Opin Drug Metab Toxicol. 2008 May;4(5):639-54. doi: 10.1517/17425255.4.5.639. Expert Opin Drug Metab Toxicol. 2008. PMID: 18484921 Review.
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Kastritis E, Terpos E, Symeonidis A, Labropoulou V, Delimpasi S, Mancuso K, Zamagni E, Katodritou E, Rivolti E, Kyrtsonis MC, Roussou M, Fotiou D, Theodorakakou F, Ntanasis-Stathopoulos I, Hatjiharissi E, Kanellias N, Migkou M, Cheliotis G, Manousou K, Gavriatopoulou M, Dimopoulos MA. Kastritis E, et al. Among authors: roussou m. Am J Hematol. 2023 Sep;98(9):E226-E229. doi: 10.1002/ajh.27001. Epub 2023 Jun 21. Am J Hematol. 2023. PMID: 37340832 Clinical Trial. No abstract available.
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy.
Theodorakakou F, Fotiou D, Spiliopoulou V, Roussou M, Malandrakis P, Ntanasis-Stathopoulos I, Migkou M, Eleutherakis-Papaiakovou E, Kanellias N, Papanikolaou A, Gavriatopoulou M, Terpos E, Dimopoulos MA, Kastritis E. Theodorakakou F, et al. Among authors: roussou m. Br J Haematol. 2023 Nov;203(3):411-415. doi: 10.1111/bjh.19042. Epub 2023 Aug 14. Br J Haematol. 2023. PMID: 37580907
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Roussou M, Eleutherakis-Papaiakovou E, Spiliopoulou V, Kastritis E, Terpos E, Dimopoulos MA, Gavriatopoulou M. Ntanasis-Stathopoulos I, et al. Among authors: roussou m. Int J Mol Sci. 2023 Jul 23;24(14):11829. doi: 10.3390/ijms241411829. Int J Mol Sci. 2023. PMID: 37511588 Free PMC article.
Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA, Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Tassidou A, Terpos E. Dimopoulos MA, et al. Among authors: roussou m. Clin Lymphoma Myeloma. 2009 Mar;9(1):59-61. doi: 10.3816/CLM.2009.n.015. Clin Lymphoma Myeloma. 2009. PMID: 19362975 Review.
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
Ntanasis-Stathopoulos I, Filippatos C, Gavriatopoulou M, Malandrakis P, Eleutherakis-Papaiakovou E, Spiliopoulou V, Syrigou RE, Theodorakakou F, Fotiou D, Migkou M, Roussou M, Kastritis E, Dimopoulos MA, Terpos E. Ntanasis-Stathopoulos I, et al. Among authors: roussou m. Diseases. 2023 Sep 18;11(3):123. doi: 10.3390/diseases11030123. Diseases. 2023. PMID: 37754319 Free PMC article.
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Fotiou D, Migkou M, Eleutherakis-Papaiakovou E, Kanellias N, Roussou M, Dialoupi I, Malandrakis P, Theodorakakou F, Kastritis E, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: roussou m. Hemasphere. 2020 May 21;4(3):e381. doi: 10.1097/HS9.0000000000000381. eCollection 2020 Jun. Hemasphere. 2020. PMID: 32647800 Free PMC article. No abstract available.
Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance.
Kastritis E, Theodorakakou F, Roussou M, Psimenou E, Gakiopoulou C, Marinaki S, Gatou A, Fotiou D, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Malandrakis P, Dialoupi I, Ntanasis-Stathopoulos I, Kostopoulos IV, Terpos E, Gavriatopoulou M, Dimopoulos MA. Kastritis E, et al. Among authors: roussou m. Br J Haematol. 2021 Apr;193(1):113-118. doi: 10.1111/bjh.17052. Epub 2020 Aug 23. Br J Haematol. 2021. PMID: 32829529 Free article.
83 results